STAAR Surgical Co. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by STAAR Surgical Company on June 22, 2026, regarding events occurring on June 18, 2026. The report details the outcomes of the Company's 2026 Annual Meeting of Shareholders, including the election of directors and the approval of corporate governance and equity plan amendments.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions and shareholder voting results.
Material Changes and Shareholder Actions
- Equity Plan Amendment: Shareholders approved Amendment No. 2 to the Amended and Restated Omnibus Equity Incentive Plan, increasing the number of shares reserved for issuance by 3,900,000.
- Director Elections: Seven directors were elected to serve until the 2027 Annual Meeting. All nominees received significant majority support, with "For" votes ranging from approximately 40.4 million to 41.1 million shares.
- Accounting Firm Ratification: Shareholders ratified the appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending January 1, 2027.
- Executive Compensation: Shareholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.
Outlook, Risks, and Management Commentary
The filing does not provide forward-looking guidance, management commentary on business strategy, or specific risk factors. It serves as a formal record of the shareholder vote results and the execution of the equity plan amendment.
Key Facts for Investor Verification
- Verify the impact of the 3.9 million share increase on potential future dilution by reviewing the full text of Amendment No. 2 (Exhibit 10.3).
- Confirm the tenure of the newly elected board members, specifically noting the term expiration at the 2027 Annual Meeting.
- Review the 2026 Proxy Statement (filed May 4, 2026) for detailed descriptions of the equity plan and executive compensation rationale.
- Note that as of the record date (April 20, 2026), there were 49,788,295 outstanding shares, with a quorum of 43,680,435 shares represented at the meeting.